Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2026)

Indivior Pharmaceuticals' Accounts Payables history runs 6 years deep, the most recent figure standing at $178.0 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 2.73% year-over-year to $178.0 million; the TTM figure through Mar 2026 stood at $178.0 million (down 2.73% YoY), while the FY2025 annual figure was $250.0 million, up 15.74% from the prior year.
• Accounts Payables was $178.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $250.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $617.0 million in Q4 2022 to a low of $178.0 million in Q1 2026.
• Historically, Accounts Payables has averaged $256.2 million across 5 years, with a median of $205.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables sank 68.4% in 2023, then advanced 15.74% in 2025.
• A 5-year view of Accounts Payables shows it stood at $617.0 million in 2022, then tumbled by 68.4% to $195.0 million in 2023, then rose by 10.77% to $216.0 million in 2024, then gained by 15.74% to $250.0 million in 2025, then declined by 28.8% to $178.0 million in 2026.
• The last three Accounts Payables figures came in at $178.0 million (Q1 2026), $250.0 million (Q4 2025), and $215.0 million (Q3 2025), per Business Quant data.